1 - 25 of 133 results for author:"Birnbaum D." in Literature citations
Results Customize
› Repeat search in UniProtKB (85)
| CXCR7 receptors facilitate the progression of colon carcinoma within lung not within liver. Guillemot E., Karimdjee-Soilihi B., Pradelli E., Benchetrit M., Goguet-Surmenian E., Millet M.A., Larbret F., Michiels J.F., Birnbaum D., Alemanno P. et al. Br. J. Cancer 107:1944-1949(2012) · Mapped (1) |
| Alterations of polycomb gene BMI1 in human myeloproliferative neoplasms. Brecqueville M., Adelaide J., Bertucci F., Finetti P., Chaffanet M., Birnbaum D., Murati A. Cell Cycle 11:3141-3142(2012) · Mapped (3) |
| Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations. Devillier R., Gelsi-Boyer V., Brecqueville M., Carbuccia N., Murati A., Vey N., Birnbaum D., Mozziconacci M.J. Am. J. Hematol. 87:659-662(2012) · Mapped (5) |
| Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. Brecqueville M., Rey J., Bertucci F., Coppin E., Finetti P., Carbuccia N., Cervera N., Gelsi-Boyer V., Arnoulet C., Gisserot O. et al. Genes Chromosomes Cancer 51:743-755(2012) · Mapped (13) |
| Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. Gelsi-Boyer V., Brecqueville M., Devillier R., Murati A., Mozziconacci M.J., Birnbaum D. J Hematol Oncol 5:12-12(2012) · Mapped (5) |
| Down-regulation of ECRG4, a candidate tumor suppressor gene, in human breast cancer. Sabatier R., Finetti P., Adelaide J., Guille A., Borg J.P., Chaffanet M., Lane L., Birnbaum D., Bertucci F. PLoS ONE 6:e27656-e27656(2011) · Mapped (1) |
| Gene expression profiling identifies sST2 as an effector of ErbB2-driven breast carcinoma cell motility, associated with metastasis. Gillibert-Duplantier J., Duthey B., Sisirak V., Salaun D., Gargi T., Tredan O., Finetti P., Bertucci F., Birnbaum D., Bendriss-Vermare N. et al. Oncogene 31:3516-3524(2012) · Mapped (8) |
| CD47-signal regulatory protein-alpha (SIRPalpha) interactions form a barrier for antibody-mediated tumor cell destruction. Zhao X.W., van Beek E.M., Schornagel K., Van der Maaden H., Van Houdt M., Otten M.A., Finetti P., Van Egmond M., Matozaki T., Kraal G. et al. Proc. Natl. Acad. Sci. U.S.A. 108:18342-18347(2011) · Mapped (8) |
| Loss of AF6/afadin, a marker of poor outcome in breast cancer, induces cell migration, invasiveness and tumor growth. Fournier G., Cabaud O., Josselin E., Chaix A., Adelaide J., Isnardon D., Restouin A., Castellano R., Dubreuil P., Chaffanet M. et al. Oncogene 30:3862-3874(2011) · Mapped (2) |
| ZNF703 gene amplification at 8p12 specifies luminal B breast cancer. Sircoulomb F., Nicolas N., Ferrari A., Finetti P., Bekhouche I., Rousselet E., Lonigro A., Adelaide J., Baudelet E., Esteyries S. et al. EMBO Mol. Med. 3:153-166(2011) · UniProtKB (3) |
| High expression of indoleamine 2,3-dioxygenase in the tumour is associated with medullary features and favourable outcome in basal-like breast carcinoma. Jacquemier J., Bertucci F., Finetti P., Esterni B., Charafe-Jauffret E., Thibult M.L., Houvenaeghel G., Van den Eynde B., Birnbaum D., Olive D. et al. Int. J. Cancer 130:96-104(2012) · Mapped (2) |
| Genome profiling of ERBB2-amplified breast cancers. Sircoulomb F., Bekhouche I., Finetti P., Adelaide J., Ben Hamida A., Bonansea J., Raynaud S., Innocenti C., Charafe-Jauffret E., Tarpin C. et al. BMC Cancer 10:539-539(2010) · Mapped (8) |
| ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Gelsi-Boyer V., Trouplin V., Roquain J., Adelaide J., Carbuccia N., Esterni B., Finetti P., Murati A., Arnoulet C., Zerazhi H. et al. Br. J. Haematol. 151:365-375(2010) · Mapped (46) |
| BARD1 homozygous deletion, a possible alternative to BRCA1 mutation in basal breast cancer. Sabatier R., Adelaide J., Finetti P., Ferrari A., Huiart L., Sobol H., Chaffanet M., Birnbaum D., Bertucci F. Genes Chromosomes Cancer 49:1143-1151(2010) · Mapped (13) |
| Loss, mutation and deregulation of L3MBTL4 in breast cancers. Addou-Klouche L., Adelaide J., Finetti P., Cervera N., Ferrari A., Bekhouche I., Sircoulomb F., Sotiriou C., Viens P., Moulessehoul S. et al. Mol. Cancer 9:213-213(2010) · Mapped (2) |
| Germline APC mutation spectrum derived from 863 genomic variations identified through a 15-year medical genetics service to French patients with FAP. Lagarde A., Rouleau E., Ferrari A., Noguchi T., Qiu J., Briaux A., Bourdon V., Remy V., Gaildrat P., Adelaide J. et al. J. Med. Genet. 47:721-722(2010) · Mapped (10) |
| Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. Rocquain J., Carbuccia N., Trouplin V., Raynaud S., Murati A., Nezri M., Tadrist Z., Olschwang S., Vey N., Birnbaum D. et al. BMC Cancer 10:401-401(2010) · Mapped (46) |
| Control of ciliogenesis by FOR20, a novel centrosome and pericentriolar satellite protein. Sedjai F., Acquaviva C., Chevrier V., Chauvin J.P., Coppin E., Aouane A., Coulier F., Tolun A., Pierres M., Birnbaum D. et al. J. Cell Sci. 123:2391-2401(2010) · UniProtKB (3) · Mapped (1) |
| Pediatric mastocytosis-associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT-phosphotransferase domain mutations. Yang Y., Letard S., Borge L., Chaix A., Hanssens K., Lopez S., Vita M., Finetti P., Birnbaum D., Bertucci F. et al. Blood 116:1114-1123(2010) · Mapped (7) |
| Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Kosmider O., Gelsi-Boyer V., Slama L., Dreyfus F., Beyne-Rauzy O., Quesnel B., Hunault-Berger M., Slama B., Vey N., Lacombe C. et al. Leukemia 24:1094-1096(2010) · Mapped (13) |
| Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias. Carbuccia N., Trouplin V., Gelsi-Boyer V., Murati A., Rocquain J., Adelaide J., Olschwang S., Xerri L., Vey N., Chaffanet M. et al. Leukemia 24:469-473(2010) · Mapped (39) |
| TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Kosmider O., Gelsi-Boyer V., Ciudad M., Racoeur C., Jooste V., Vey N., Quesnel B., Fenaux P., Bastie J.N., Beyne-Rauzy O. et al. Haematologica 94:1676-1681(2009) · Mapped (2) |
| TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Kosmider O., Gelsi-Boyer V., Cheok M., Grabar S., Della-Valle V., Picard F., Viguie F., Quesnel B., Beyne-Rauzy O., Solary E. et al. Blood 114:3285-3291(2009) · Mapped (2) |
| Mutations of ASXL1 gene in myeloproliferative neoplasms. Carbuccia N., Murati A., Trouplin V., Brecqueville M., Adelaide J., Rey J., Vainchenker W., Bernard O.A., Chaffanet M., Vey N. et al. Leukemia 23:2183-2186(2009) · Mapped (13) |
| Abnormal mammary gland development in MMTV-CBLC transgenic mouse. Fiore F., Estebe B., Gibier P., Orsoni J.C., Courbard J.R., Chodosh L.A., Birnbaum D., Delapeyriere O. In Vivo 23:225-228(2009) · Mapped (3) |